However, we have shown that the same UniCAR T-cells can be efficiently redirected with either anti-CD10 and/or anti-CD19 TMs, which might be helpful to overcome tumor escape variants and tumor heterogeneity, enabling an overall enhanced anti-tumor effect in patients. Here, CD19 is linked to neoplasm.